Germany's Merck Scraps MS Drug Cladribine After Regulators' Rebuff
This article was originally published in The Pink Sheet Daily
Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.
You may also be interested in...
Merck KGaA plans to cut headcount and reduce costs, although employees are to be asked first to identify pragmatic cost-saving strategies.
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.